Trevi Therapeutics reports positive results in the Phase 2 Cough And NALbuphine (CANAL) trial of its Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF).
“It is very promising to see such a significant reduction in chronic cough in IPF patients with nalbuphine ER,” said Peter Dicpinigaitis, MD, Professor of Medicine at the Albert Einstein College of Medicine, and Director of the Montefiore Cough Center, in New York. “There is a large unmet need for chronic cough therapies and I believe there is broad potential to improve patients’ lives with an oral therapy with a central mechanism of action.”